Physician profile
Swati Pathak
NPI 1407012602
$19,135.97
in general payments reported to CMS, 2019-2025
82 companies · $5,434 in 2025
The $5,434 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.31 · 2020: $299 · 2021: $2,304 · 2022: $2,929 · 2023: $3,909 · 2024: $4,216 · 2025: $5,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,841.34 |
| Education | $716.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,638.06 | 2020-2025 | Enhertu, Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,465.39 | 2021-2025 | Piqray, Kisqali |
| Celgene Corporation | $1,196.54 | 2021-2025 | Reblozyl, Pomalyst, Breyanzi |
| Janssen Biotech, INC. | $1,139.09 | 2021-2025 | Darzalex, Rybrevant, Tecvayli |
| Pfizer INC. | $1,073.23 | 2020-2025 | |
| Astellas Pharma US INC | $850.09 | 2020-2025 | Xtandi, Padcev, Vyloy |
| Merck Sharp & Dohme LLC | $848.93 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $764.20 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Incyte Corporation | $684.44 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Sobi, INC | $561.91 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $559.75 | 2021-2025 | |
| Seagen INC. | $534.82 | 2020-2025 | Adcetris, Tivdak |
| Abbvie INC. | $470.56 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $438.09 | 2021-2024 | Opdivo, Opdualag |
| Jazz Pharmaceuticals INC. | $361.81 | 2021-2025 |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $336.62 | 2019-2025 | Ojjaara, Blenrep |
| Myriad Genetic Laboratories, INC. | $328.81 | 2022-2024 | Myrisk |
| Eisai INC. | $320.91 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $316.12 | 2021-2025 | Libtayo |
| Genzyme Corporation | $272.83 | 2021-2025 | |
| Array Biopharma INC | $263.82 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $253.70 | 2020-2022 | |
| Pharmacosmos Therapeutics INC. | $249.44 | 2023-2025 | Monoferric, Cosela |
| Genentech USA, INC. | $206.37 | 2021-2025 | Venclexta, Phesgo, Polivy |
| Gilead Sciences, INC. | $188.97 | 2023-2025 | Trodelvy |
| Tersera Therapeutics LLC | $188.96 | 2023-2025 | Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $166.36 | 2022-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Alexion Pharmaceuticals, INC. | $164.29 | 2022-2025 | Ultomiris |
| Dendreon Pharmaceuticals LLC | $155.49 | 2023-2025 | Provenge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.66 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $133.43 | 2021-2025 | Xpovio |
| Dova Pharmaceuticals | $132.09 | 2020-2021 | |
| Emd Serono, INC. | $130.17 | 2022-2025 | |
| Pharmaessentia USA Corporation | $126.64 | 2022-2025 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $118.89 | 2021-2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $117.00 | 2021-2025 | Rezlidhia, Gavreto, Tavalisse |
| Lilly USA, LLC | $112.33 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Alnylam Pharmaceuticals INC. | $111.34 | 2021-2025 | Givlaari |
| Foundation Medicine, INC. | $109.62 | 2020-2023 | |
| Mirati Therapeutics, INC. | $106.39 | 2023-2024 | Krazati |
| Taiho Oncology, INC. | $104.10 | 2021-2024 | |
| Puma Biotechnology, INC. | $97.69 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $97.67 | 2020-2025 | Pyrukynd |
| G1 Therapeutics, INC. | $95.82 | 2022-2023 | Cosela |
| Stemline Therapeutics INC. | $94.85 | 2023-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $86.60 | 2021-2025 | Fotivda |
| Geron Corporation | $78.96 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $77.41 | 2022-2025 | Ayvakit |
| Morphosys, US INC. | $73.46 | 2021-2023 | Monjuvi |
| Kyowa Kirin, INC. | $72.62 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $69.98 | 2022-2024 | |
| Adc Therapeutics America, INC. | $69.91 | 2021-2025 | |
| Global Blood Therapeutics, INC. | $65.13 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $60.20 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $53.96 | 2021-2025 | Somatuline Depot, Onivyde |
| Myovant Sciences INC. | $52.57 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $38.17 | 2020-2025 | Romvimza, Qinlock |
| Coherus Oncology, INC. | $37.12 | 2021 | |
| Springworks Therapeutics, INC. | $35.04 | 2025 | Ogsiveo |
| Immunocore Limited | $32.99 | 2025 | Kimmtrak |
| Amag Pharmaceuticals, INC. | $29.83 | 2021 | |
| Iovance Biotherapeutics, INC. | $28.63 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $25.76 | 2021 | |
| Immunogen, INC. | $25.26 | 2023 | Elahere |
| Acceleron Pharma, INC. | $23.93 | 2021 | |
| Adaptive Biotechnologies Corporation | $22.60 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.91 | 2025 | Danziten |
| Tolmar, INC. | $20.68 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $20.68 | 2025 | Rubraca |
| Menarini Silicon Biosystems, INC. | $20.21 | 2024 | |
| Sumitomo Pharma America, INC. | $20.18 | 2025 | Orgovyx |
| Apellis Pharmaceuticals, INC. | $19.31 | 2022 | |
| Recordati_rare_diseases_inc. | $18.07 | 2023 | Sylvant |
| Genmab U.S., INC. | $17.68 | 2024 | Epkinly |
| Progenics Pharmaceuticals, INC. | $16.96 | 2024 | |
| Csl Behring | $16.36 | 2024 | Afstyla, Idelvion |
| Novocure INC. | $15.72 | 2025 | Optune Lua (Novottf-200t) |
| Macrogenics, INC. | $14.92 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $14.78 | 2024 | Sancuso |
| Ge Healthcare | $11.03 | 2021 | |
| Veracyte, INC. | $5.06 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Enhertu $953Reblozyl $653Keytruda $556Kisqali $480Lynparza $429Venclexta $427Xtandi $408Nubeqa $357Darzalex $325Adcetris $287Pluvicto $276Rybrevant $272Imfinzi $269Doptelet $256Jakafi $250Lenvima $246Elrexfio $243Orgovyx $242Myrisk $240Libtayo $232Monoferric $217Monjuvi $214Talzenna $202Braftovi $198Lutathera $191Zoladex $189Vonjo $187Scemblix $180Tukysa $178Stivarga $175Vitrakvi $175Padcev $168Tecvayli $168Mektovi $165Imbruvica $158Sarclisa $158Provenge $155Zynyz $152Bosulif $151Zepzelca $151Piqray $149Erleada $136Talvey $135Pomalyst $134Ultomiris $129Lorbrena $125Ojjaara $113Jaypirca $112Verzenio $112Balversa $110Krazati $106Besremi $106Xpovio $105Opdualag $97.61Epkinly $97.41Orserdu $94.85Ibrance $93.79Akeega $90.63Breyanzi $88.98Cosela $86.31Ayvakit $82.09Rytelo $78.96Fabhalta $78.07Opdivo $77.80Welireg $76.94Fotivda $69.46Promacta $68.30Inqovi $66.80Lonsurf $66.80Trodelvy $63.79Givlaari $63.65Odomzo $60.20Yonsa $60.20Datroway $59.11Tasigna $55.22Oxbryta $53.56Zynlonta $52.99Vyloy $52.59Pyrukynd $51.52Alunbrig $49.59Gavreto $48.73Tibsovo $47.86Besponsa $45.91Tivdak $44.25Fruzaqla $43.54Rubraca $41.36Keytruda Qlex $39.61Synagis $38.60Comirnaty $38.07Xalkori $37.86Phesgo $37.41Ogsiveo $35.04Polivy $34.03Paxlovid $33.85Ninlaro $33.68Kimmtrak $32.99Rezlidhia $32.75Tavalisse $32.75Vanflyta $32.47Lupron Depot $30.67
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.